Document is current
Any future updates will be listed below
-
Authors
Kim-McManus, Olivia https://orcid.org/0000-0002-4785-7795
Gleeson, Joseph G. https://orcid.org/0000-0002-0889-9220
Mignon, Laurence
Smith Fine, Amena
Yan, Winston
Nolen, Nicole https://orcid.org/0009-0002-3052-289X
Demarest, Scott
Berry-Kravis, Elizabeth https://orcid.org/0000-0001-7099-1522
Finkel, Richard https://orcid.org/0000-0002-9351-7054
Leonard, Stefanie
Finlayson, Samuel
Augustine, Erika
Lyon, Gholson J. https://orcid.org/0000-0002-5869-0716
Schule, Rebecca
Yu, Timothy https://orcid.org/0000-0003-2988-7701
-
Funding
Funding for this research was provided by:
California Institute for Regenerative Medicine
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 1 November 2024
First Online: 12 November 2024
Competing interests
: Joseph Gleeson serves as a consultant for Ionis Pharmaceuticals, Neurocrine Pharmaceuticals, and the n-Lorem Foundation. Winston Yan is a founder, employee, and shareholder of Arbor Biotechnologies, and serves as President and Board Member of the N=1 Collaborative. Timothy Yu has received research support from EveryONE Medicines, and volunteer Board Member for the N=1 Collaborative, the Oligonucleotide Therapeutics Society, and the Society for RNA Therapeutics, and a volunteer advisor to several rare disease foundations. The remaining authors declare no competing interests.
